We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

A New Way of Diagnosing Alzheimer's – Right Under Your Nose


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "A New Way of Diagnosing Alzheimer's – Right Under Your Nose"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

Many countries with a rapidly ageing population are facing increasing numbers of patients with dementia, of which Alzheimer's disease (AD) is the most representative type. Unfortunately, AD has no complete cure yet; but, some treatments have been proven to delay its progression. Of course, this means that timely diagnosis while the symptoms are still mild is essential to maximize a patient's quality of life.

However, currently available technologies for diagnosing AD are limited because they involve expensive machinery and invasive or inconvenient procedures. Now, in a recent study published in Scientific Reports, scientists from Daegu Gyeongbuk Institute of Science and Technology, Korea, hint at a novel way of diagnosing AD in a much simpler way --collecting and analyzing specific proteins in nasal discharge samples.

Professor Cheil Moon, who led the study, explains how they came up with the idea: "In 2017, we found that olfactory dysfunction occurred in the early stages of AD in mice and suggested that the cause of the symptoms was induced by soluble species of amyloid-β (Aβ) oligomer accumulations in the peripheral olfactory system. We hypothesized that soluble Aβ oligomers could be detectable in nasal discharge and that they may be a useful parameter to monitor disease progression." To test their hypothesis, they gathered and compared nasal discharge samples from 39 patients with AD and 21 people from an age-matched control group.

They found that the levels of two particular Aβ oligomers (the aggregated forms of Aβ implicated as characteristic of Alzheimer's) were consistently higher in patients from the AD group. What's more, the levels of the "soluble" form of this protein could be used to not only separate healthy subjects from patients with AD, but also predict the onset and progression of AD over a three-year period.

Although further research will be required to better understand the link between Aβ oligomers in nasal discharge and the cognitive impairments related to AD, the results are certainly promising. Prof Moon remarks, "Routine nasal discharge screenings would be a better option to screen for AD because of its various advantages, such as its relatively low cost and non-invasive nature. The results of our study introduce a novel and simple approach to assess AD progression."

This new diagnostic technique will hopefully help in simpler and faster detection of Alzheimer's and improving the disease outcome, thus bringing much needed relief to millions suffering from the Alzheimer's worldwide.

Reference: Yoo, S.-J., Son, G., Bae, J., Kim, S. Y., Yoo, Y. K., Park, D., Baek, S. Y., Chang, K.-A., Suh, Y.-H., Lee, Y.-B., Hwang, K. S., Kim, Y., & Moon, C. (2020). Longitudinal profiling of oligomeric Aβ in human nasal discharge reflecting cognitive decline in probable Alzheimer’s disease. Scientific Reports, 10(1), 11234. https://doi.org/10.1038/s41598-020-68148-2

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement